A case of advanced ankylosing spondylitis complicated with cervical myelopathy due to ossification of yellow ligament in which bone histomorphometry demonstrated delayed calcification
暂无分享,去创建一个
[1] Man R Shim. Efficacy of TNF inhibitors in advanced ankylosing spondylitis with total spinal fusion: case report and review of literature , 2019, Open access rheumatology : research and reviews.
[2] N. Endo,et al. Bone Histomorphometric Findings in Ankylosing Spondylitis: A Case Report , 2018, Journal of Bone Biology and Osteoporosis.
[3] S. Grazio,et al. Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries , 2018, Drugs in context.
[4] A. Akyol,et al. Vitamin D levels in patients with ankylosing spondylitis: Is it related to disease activity? , 2018, Pakistan journal of medical sciences.
[5] L. Idolazzi,et al. Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis , 2018, Clinical Rheumatology.
[6] C. Niu,et al. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL , 2017, BMC Musculoskeletal Disorders.
[7] M. Dougados,et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.
[8] R. Landewé,et al. Ankylosing Spondylitis and Axial Spondyloarthritis. , 2016, The New England journal of medicine.
[9] P. Tugwell,et al. TNF-alpha inhibitors for ankylosing spondylitis. , 2015, The Cochrane database of systematic reviews.
[10] C. O'Morain,et al. Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease , 2015, Digestive Diseases and Sciences.
[11] K. Nishizawa,et al. Prevalence, Distribution, and Morphology of Thoracic Ossification of the Yellow Ligament in Japanese: Results of CT-Based Cross-Sectional Study , 2013, Spine.
[12] K. Yonenobu,et al. JOA Back Pain Evaluation Questionnaire (JOABPEQ)/JOA Cervical Myelopathy Evaluation Questionnaire (JOACMEQ) The report on the development of revised versions April 16, 2007 , 2009, Journal of Orthopaedic Science.
[13] I. Olivieri,et al. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. , 2008, Rheumatology.
[14] K. Yonenobu,et al. The Subcommittee of the Clinical Outcome Committee of the Japanese Orthopaedic Association on Low Back Pain and Cervical Myelopathy Evaluation , 2009 .
[15] B. Shadbolt,et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis , 2008, Internal medicine journal.
[16] 紺野愼一,et al. 日本整形外科学会腰痛評価質問票JOA Back Pain Evaluation Questionnaire(JOABPEQ)/日本整形外科学会頚部脊髄症評価質問票JOA Cervical Myelopathy Evaluation Questionnaire(JOACMEQ)作成報告書(平成19年4月16日) , 2008 .
[17] P. Cabre,et al. Ossification of the Ligamenta Flava With Severe Myelopathy in a Black Patient: A Case Report , 1998, Spine.
[18] Y. S. Lee,et al. Skeletal status of men with early and late ankylosing spondylitis. , 1997, The American journal of medicine.
[19] V. Szejnfeld,et al. Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. , 1997, The Journal of rheumatology.
[20] A. Freemont,et al. Age related histomorphometric changes in bone in normal British men and women. , 1994, Journal of clinical pathology.